Research · Sep 3, 2026
[MCK] McKesson Thesis 2026: GLP-1 Distribution Volume Anchors Pharmaceutical Cycle
McKesson Corporation FY2025 revenue ~$355-365B (+8-12%) with adj. EPS ~$32-34 reflecting continued pharmaceutical distribution volume growth + selected GLP-1 weight-loss drug tailwind (Ozempic + Wegovy + Mounjaro + Zepbound distribution) + selected pricing modest + selected operational discipline + selected opioid litigation cost continuation. Largest US pharmaceutical distribution + healthcare services company; founded 1833 by John McKesson + Charles Olcott as small drug import in NYC. One of Big 3 US pharmaceutical distributors (alongside Cencora ABC + Cardinal Health) selected dominating US drug distribution. 4 segments: US Pharmaceutical ~88% ($315B) + Prescription Technology Solutions ~3% + Medical-Surgical Solutions ~3% + International ~6% (primarily Canada Rexall + selected smaller European post-divestitures). Selected ~80% of US hospitals served + ~50K+ pharmacy customer base. CEO Brian Tyler since April 1, 2019 (succeeded John Hammergren CEO 1999-2019 who transitioned amid selected opioid litigation criticism; Tyler ex-McKesson President; ~25-year McKesson career). Tyler tenure executed continued operational excellence + opioid litigation $7.4B settlement 2022 (Big 3 distributors combined ~$26B; multi-year payments through ~2040 ~$0.5-0.8B annual McKesson) + selected international portfolio optimization (selected European operations divestitures) + GLP-1 volume tailwind capture + capital return acceleration. GLP-1 weight-loss drug class creating selected unprecedented prescription volume growth (industry GLP-1 sales selected $30B+ in 2024 → $50B+ in 2026 → $100B+ by 2030 projected). Capital return: dividend $2.48-2.62/share + buybacks $3-4B (~3-5%/yr share count reduction); net debt $3-5B (modest); A3/BBB+ investment grade. FY2026 thesis: GLP-1 distribution volume + scale moat + capital return. Risks: drug pricing reform, opioid litigation continuing, generic substitution.